Press releases
Shionogi-ViiV Healthcare announces initial data from pivotal phase III study of dolutegravir in HIV
SPRING-2 study meets primary endpoint of non-inferiority of dolutegravir compared to raltegravir over 48 weeks in treatment-naïve HIV patients.
GSK and Theravance announce completion of the Relovair™* registrational programme and topline results from Relovair™ vs. Advair® phase III studies in COPD
GSK and Theravance, Inc. today announced the registrational programme for Relovair™ is now complete. In addition, results from two studies for the once-daily investigational medicine Relovair™ in patients with COPD and results from a study to evaluate the efficacy and safety of FF and FP compared to placebo in the treatment of persistent asthma in adults and adolescents were announced.
GSK confirms significant investments in UK manufacturing: Ulverston in Cumbria selected as site of new biopharmaceutical factory
GSK today confirmed that it will invest more than £500m in the UK across its manufacturing sites to increase production of key active ingredients for its pharmaceutical products and vaccines.
GSK announces positive vote from FDA panel for pazopanib in certain advanced soft tissue sarcomas
GSK announced today that the Oncologic Drugs Advisory Committee (ODAC) to the US FDA voted 11 to 2 that evidence from clinical studies support a favourable benefit – risk assessment for use of Votrient in treating patients with advanced soft tissue sarcoma.
GlaxoSmithKline provides further update on divestment of non-core over-the-counter (OTC) brands
In February 2011, GSK announced its intention to divest non-core Consumer Healthcare OTC products predominantly in the United States and Europe with aggregate sales of approximately £500 million.
GSK reinforces commitment to youth training with launch of new UK apprenticeship programme
GSK today announced the launch of a new multi-disciplinary apprenticeship scheme. The programme, which will sit alongside GSK’s established graduate and undergraduate recruitment schemes, is aimed at 16-24 year olds.
Regulatory Update: GSK announces submissions for two influenza vaccines
GlaxoSmithKline [GSK] announced today that it has submitted regulatory files for two of its influenza vaccines currently in development.
Innovative UK research project to study the value medicines bring to patients in the real world
Unique collaboration to ensure medicines under development meet patient and healthcare system needs.
GSK and Daiichi Sankyo vaccines joint venture to become largest vaccines company in Japan
GlaxoSmithKline (GSK) today announced that it has signed an agreement with Daiichi Sankyo Co., Ltd. to form a Joint Venture (JV) which is expected to create the number one vaccines company in Japan.
GlaxoSmithKline receives positive opinion in Europe from the CHMP for Nimenrix®
GSK announced that the EMA's Committee for Medicinal Products for Human Use has issued a positive opinion recommending marketing authorisation for Nimenrix® for active immunisation against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W-135 and Y.
